Adarx Pharmaceuticals (ADRX)

Market Price (9/26/2026): $18.56 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

Adarx Pharmaceuticals (ADRX)

Market Price (9/26/2026): $18.56
Market Cap: $-
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.

Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%

Weak multi-year price returns
2Y Excs Rtn is -36%, 3Y Excs Rtn is -76%

0	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
1	Trading close to highs Dist 52W High is 0.0%, Dist 3Y High is 0.0%
2	Weak multi-year price returns 2Y Excs Rtn is -36%, 3Y Excs Rtn is -76%

Valuation & Metrics

	9/26/26	2025	2024
Share Price	$18.56	�	�
Mkt Cap ($ Mil)	0.0	-	-
+ Debt ($ Mil)	0.0	0.0	0.0
- Cash ($ Mil)	0.0	0.0	0.0
TEV ($ Mil)	0.0
Valuation Ratios
P/S	-	-	-
P/EBIT	-	-	-
P/E	-	-	-
P/FCF	-	-	-
Sector Ratios (* = sector average)
P/S *	4.1	4.2	4.0
P/EBIT *	-1.9	-1.8	-1.5
P/E *	-1.8	-1.9	-1.7
P/FCF *	-1.9	-1.8	-1.4

	9/26/26	2025	2024
Share Price	$18.56	�	�
Mkt Cap ($ Mil)	0.0	-	-
+ Debt ($ Mil)	0.0	0.0	0.0
- Cash ($ Mil)	0.0	0.0	0.0
TEV ($ Mil)	0.0
Valuation Ratios
P/S	-	-	-
P/EBIT	-	-	-
P/E	-	-	-
P/FCF	-	-	-
Sector Ratios (* = sector average)
P/S *	4.1	4.2	4.0
P/EBIT *	-1.9	-1.8	-1.5
P/E *	-1.8	-1.9	-1.7
P/FCF *	-1.9	-1.8	-1.4

null

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Employees	100	6302026	Link
Number of Investors	19	8022023	Link
Total Funding Raised	353M	8022023	Link
Number of Clinical-Stage Programs	3	9212026	Link
Number of Preclinical Programs	2	9212026	Link
Number of Patent Applications	1	8312023	Link
Upfront Payment from AbbVie Collaboration	335M	9102026	Link
Potential Milestone Payments from AbbVie Collaboration	7.45B	9102026	Link

Price Chart

null

No Events

Why The Stock Moved

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

5/31/2026 to 9/25/2026

	Return	Correlation
ADRX
Market (SPY)	2.2%	�
Sector (XLV)	14.7%	�

Fundamental Drivers

null
null

Market Drivers

2/28/2026 to 9/25/2026

	Return	Correlation
ADRX
Market (SPY)	13.0%	�
Sector (XLV)	7.5%	�

Fundamental Drivers

null
null

Market Drivers

8/31/2025 to 9/25/2026

	Return	Correlation
ADRX
Market (SPY)	20.9%	�
Sector (XLV)	26.4%	�

Fundamental Drivers

null
null

Market Drivers

8/31/2023 to 9/25/2026

	Return	Correlation
ADRX
Market (SPY)	77.8%	�
Sector (XLV)	34.7%	�

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
ADRX Return	-	-	-	-	-	-	-
Peers Return	14%	15%	15%	-6%	100%	-14%	141%
S&P 500 Return	27%	-19%	24%	23%	16%	13%	105%
Monthly Win Rates [3]
ADRX Win Rate	-	-	-	-	-	-
Peers Win Rate	52%	57%	50%	42%	62%	47%
S&P 500 Win Rate	75%	42%	67%	75%	67%	56%
Max Drawdowns [4]
ADRX Max Drawdown	-	-	-	-	-	-
Peers Max Drawdown	-32%	-32%	-27%	-37%	-34%	-35%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALNY, ARWR, IONS, LLY, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/25/2026 (YTD)

ADRX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2025 US Tariff Shock
% Loss	-11.7%	-18.8%
% Gain to Breakeven	13.3%	23.1%
Time to Breakeven	142 days	79 days
2022 Inflation Shock & Fed Tightening
% Loss	-13.8%	-24.5%
% Gain to Breakeven	15.9%	32.4%
Time to Breakeven	166 days	427 days
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-15.0%	-19.2%
% Gain to Breakeven	17.6%	23.8%
Time to Breakeven	191 days	105 days
2015-2016 China Devaluation / Global Growth Scare
% Loss	-15.9%	-12.2%
% Gain to Breakeven	18.9%	13.9%
Time to Breakeven	165 days	62 days
2011 US Debt Ceiling Crisis & European Contagion
% Loss	-15.8%	-17.9%
% Gain to Breakeven	18.8%	21.8%
Time to Breakeven	153 days	123 days

Compare to ALNY, ARWR, IONS, LLY, REGN

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

ADRX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Event	XLV	S&P 500
2020 COVID-19 Crash
% Loss	-27.9%	-33.7%
% Gain to Breakeven	38.8%	50.9%
Time to Breakeven	77 days	140 days
2008-2009 Global Financial Crisis
% Loss	-37.9%	-53.4%
% Gain to Breakeven	61.1%	114.4%
Time to Breakeven	767 days	1085 days

Compare to ALNY, ARWR, IONS, LLY, REGN

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Adarx Pharmaceuticals (ADRX)

Business Description

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

Interactive Breakdown

null

null

Better Bets vs. Adarx Pharmaceuticals (ADRX)

null

Peer Outperformance in Biotechnology

null

Share of Biotechnology constituents that ADRX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.

—

insufficient peer history

—

insufficient peer history

—

insufficient peer history

null

Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is ADRX's own industry. Use this to see which corners of the sector have carried the returns.

Industry	Names	1Y med	3Y med	5Y med	Top 3 by 5Y
Health Care Distributors	6	10.8%	42.7%	87.6%	CAH 380% · MCK 337% · COR 165%
Managed Health Care	8	34.8%	-9.4%	3.1%	OSCR 74% · HQY 34% · ELV 12%
Health Care Services	20	21.2%	37.1%	0.2%	HIMS 263% · RDNT 142% · DGX 70%
Health Care Facilities	24	4.5%	14.6%	-0.9%	NHC 275% · THC 264% · ENSG 135%
Health Care Equipment	50	-1.7%	-1.1%	-19.3%	POCI 11475% · UFPT 375% · GKOS 205%
Health Care Supplies	12	29.6%	-7.7%	-38.4%	LNTH 270% · HAE 52% · MMSI 21%
Pharmaceuticals	62	-8.9%	7.3%	-41.9%	LQDA 2284% · INDV 1094% · ETON 1051%
Life Sciences Tools & Services	113	1.3%	-10.1%	-67.2%	SNWV 1957% · NTRA 249% · MEDP 212%
Health Care Technology	21	-32.6%	-53.0%	-78.2%	SPOK 72% · HSTM 2% · VEEV -6%
Biotechnology ←	375	-8.7%	-23.0%	-79.7%	CELZ 1371% · DNTH 1085% · ELVN 965%

Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Latest Trefis Analyses

null

Trade Ideas

Select ideas related to ADRX.

null

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AESI	Atlas Energy Solutions	1.6	13.5%	32.4%
PPLI	People	3.0	11.3%	-4.1%
WNC	Wabash National	0.5	11.3%	54.3%
MXL	MaxLinear	8.4	10.0%	438.4%
VECO	Veeco Instruments	3.0	9.3%	73.8%
VIAV	Viavi Solutions	9.7	9.3%	128.3%
BE	Bloom Energy	82.9	8.3%	232.3%
CRDO	Credo Technology	39.0	7.7%	46.6%
NUTX	Nutex Health	1.5	7.6%	33.7%
STAA	Staar Surgical	1.0	7.5%	-11.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ONT	Onterris	0.5	-16.8%	-43.6%
KDK	Kodiak AI	0.5	-12.6%	-77.7%
ZS	Zscaler	31.0	-10.1%	-14.2%
SLI	Standard Lithium	0.5	-9.7%	-58.4%
RPD	Rapid7	0.8	-9.6%	-23.6%
NGNE	Neurogene	0.6	-9.4%	37.4%
FRVO	Fervo Energy	2.4	-9.2%	-58.5%
BYND	Beyond Meat	4.2	-9.1%	-66.1%
PURR	Hyperliquid Strategies	1.6	-8.8%	261.0%
ADBT	Advasa	0.1	-8.8%	-98.2%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
GRAL	GRAIL	5.5	57.1%	48.3%
SECZ	Securitize	2.4	47.0%	29.8%
BALY	Ballys	0.8	34.5%	-15.3%
MRNA	Moderna	79.2	29.1%	574.4%
VICR	Vicor	13.0	26.6%	157.3%
QMCO	Quantum	0.7	26.3%	391.2%
OUST	Ouster	2.9	24.7%	102.0%
ARHS	Arhaus	1.4	24.6%	-9.1%
BAND	Bandwidth	2.0	23.1%	300.1%
VKTX	Viking Therapeutics	4.1	22.7%	1.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
XNDU	Xanadu Quantum Technologies	1.5	-32.9%	-56.7%
CGEM	Cullinan Therapeutics	0.9	-29.7%	43.1%
ALKT	Alkami Technology	1.5	-27.9%	-40.2%
BYND	Beyond Meat	4.2	-27.5%	-66.1%
KDK	Kodiak AI	0.5	-25.9%	-77.7%
GEN	Gen Digital	13.0	-25.5%	-19.3%
PBLS	Parabilis Medicines	0.9	-25.2%	-1.3%
CTEV	Claritev	0.4	-24.7%	-45.7%
ACAD	ACADIA Pharmaceuticals	3.5	-24.2%	-22.6%
ONT	Onterris	0.5	-22.7%	-43.6%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SECZ	Securitize	2.4	134.7%	29.8%
GRAL	GRAIL	5.5	59.4%	48.3%
BALY	Ballys	0.8	54.0%	-15.3%
MXL	MaxLinear	8.4	49.0%	438.4%
SDGR	Schrodinger	2.2	48.2%	61.4%
FEIM	Frequency Electronics	0.9	45.9%	64.2%
OKTA	Okta	34.4	45.2%	125.7%
VICR	Vicor	13.0	43.0%	157.3%
ACVA	ACV Auctions	1.8	42.9%	30.4%
FWDI	Forward Industries	0.7	42.0%	27.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
ADBT	Advasa	0.1	-97.9%	-98.2%
ALMS	Alumis	0.9	-69.9%	-27.3%
XNDU	Xanadu Quantum Technologies	1.5	-51.5%	-56.7%
RARE	Ultragenyx Pharmaceutical	1.5	-45.2%	-37.0%
SWMR	Swarmer	0.3	-44.0%	-33.1%
IMUX	Immunic	0.4	-43.3%	75.1%
XENE	Xenon Pharmaceuticals	3.7	-42.1%	-17.6%
BYND	Beyond Meat	4.2	-41.4%	-66.1%
ALHC	Alignment Healthcare	1.7	-40.9%	-58.4%
PRLD	Prelude Therapeutics	0.4	-40.9%	33.6%

Peer Comparisons

Peers to compare with:

Financials

	ADRX	ALNY	ARWR	IONS	LLY	REGN	Median
Name	Adarx Ph.	Alnylam .	Arrowhea.	Ionis Ph.	Eli Lilly	Regenero.
Mkt Price	19.35	255.96	65.92	44.50	1,183.46	788.04	160.94
Mkt Cap	-	34.2	9.5	7.4	1,056.1	81.0	34.2
Rev LTM	-	4,804	669	874	79,666	15,535	4,804
Op Inc LTM	-	1,000	-226	-594	39,608	4,174	1,000
FCF LTM	-	820	-75	-568	13,560	3,575	820
FCF 3Y Avg	-	354	-208	-410	3,294	3,439	354
CFO LTM	-	912	-59	-496	28,083	4,681	912
CFO 3Y Avg	-	414	-130	-358	14,510	4,498	414

Growth & Margins

	ADRX	ALNY	ARWR	IONS	LLY	REGN	Median
Name	Adarx Ph.	Alnylam .	Arrowhea.	Ionis Ph.	Eli Lilly	Regenero.
Rev Chg LTM	-	95.1%	16.8%	-7.4%	49.6%	9.3%	16.8%
Rev Chg 3Y Avg	-	63.2%	913.6%	12.5%	39.4%	7.0%	39.4%
Rev Chg Q	-	66.9%	171.0%	-40.7%	47.7%	16.7%	47.7%
QoQ Delta Rev Chg LTM	-	12.1%	7.6%	-17.4%	10.3%	4.1%	7.6%
Op Inc Chg LTM	-	654.9%	-109.7%	-123.0%	76.5%	6.1%	6.1%
Op Inc Chg 3Y Avg	-	163.9%	-77.5%	-24.5%	71.3%	-1.7%	-1.7%
Op Mgn LTM	-	20.8%	-33.8%	-68.0%	49.7%	26.9%	20.8%
Op Mgn 3Y Avg	-	6.0%	-945.9%	-47.0%	42.1%	28.2%	6.0%
QoQ Delta Op Mgn LTM	-	3.3%	1.9%	-34.7%	2.4%	1.1%	1.9%
CFO/Rev LTM	-	19.0%	-8.8%	-56.8%	35.3%	30.1%	19.0%
CFO/Rev 3Y Avg	-	11.1%	-598.1%	-41.2%	22.5%	31.2%	11.1%
FCF/Rev LTM	-	17.1%	-11.2%	-64.9%	17.0%	23.0%	17.0%
FCF/Rev 3Y Avg	-	9.2%	-908.4%	-47.1%	2.5%	23.9%	2.5%

Valuation

	ADRX	ALNY	ARWR	IONS	LLY	REGN	Median
Name	Adarx Ph.	Alnylam .	Arrowhea.	Ionis Ph.	Eli Lilly	Regenero.
Mkt Cap	-	34.2	9.5	7.4	1,056.1	81.0	34.2
P/S	-	7.1	14.1	8.4	13.3	5.2	8.4
P/Op Inc	-	34.2	-41.7	-12.4	26.7	19.4	19.4
P/EBIT	-	30.4	-59.3	-15.4	25.6	15.5	15.5
P/E	-	42.3	-29.5	-13.0	39.5	18.7	18.7
P/CFO	-	37.5	-160.0	-14.8	37.6	17.3	17.3
Total Yield	-	2.4%	-3.4%	-7.7%	3.1%	5.8%	2.4%
Dividend Yield	-	0.0%	0.0%	0.0%	0.5%	0.5%	0.0%
FCF Yield 3Y Avg	-	1.0%	-6.0%	-4.8%	0.3%	4.9%	0.3%
D/E	-	0.0	0.1	0.2	0.1	0.0	0.1
Net D/E	-	-0.1	-0.1	-0.1	0.0	-0.1	-0.1

Returns

	ADRX	ALNY	ARWR	IONS	LLY	REGN	Median
Name	Adarx Ph.	Alnylam .	Arrowhea.	Ionis Ph.	Eli Lilly	Regenero.
1M Rtn	0.0%	7.1%	-26.0%	-29.8%	-0.5%	-3.3%	-1.9%
3M Rtn	0.0%	-12.2%	-16.4%	-45.2%	-1.9%	24.7%	-7.0%
6M Rtn	0.0%	-19.3%	14.1%	-38.3%	35.2%	7.1%	3.6%
12M Rtn	0.0%	-43.1%	108.2%	-29.3%	66.7%	42.6%	21.3%
3Y Rtn	0.0%	46.2%	151.6%	-3.8%	119.6%	-4.4%	23.1%
1M Excs Rtn	-0.9%	6.2%	-26.9%	-30.6%	-1.4%	-4.2%	-2.8%
3M Excs Rtn	-5.3%	-17.4%	-21.7%	-50.5%	-7.2%	19.4%	-12.3%
6M Excs Rtn	-19.5%	-41.6%	-11.1%	-59.6%	12.8%	-15.1%	-17.3%
12M Excs Rtn	-16.7%	-60.8%	84.1%	-47.1%	43.9%	20.6%	2.0%
3Y Excs Rtn	-75.9%	-30.1%	68.2%	-71.3%	36.2%	-80.2%	-50.7%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Clinical Pipeline

null

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024
Period End	0/0/-1	12/31/2025	12/31/2024
Filing Date	0/0/-1	9/4/2026	9/4/2026
Key Financials
Total Revenue	-	3	0
Gross Profit	-	-	-
EBITDA	-	-86	-57
Operating Income	-	-88	-58
Net Income	-	-73	-46
EPS	-	-	-
Growth Rates
Total Revenue Growth	-	∞%	-
EBITDA Growth	-	-51.7%	-
Operating Income Growth	-	-51.7%	-
Net Income Growth	-	-57.7%	-
Margins
Gross Margin	-	-	-
EBITDA Margin	-	-2494.6%	-
Operating Income Margin	-	-2562.0%	-
Net Income Margin	-	-2119.1%	-
Cash & Debt
Total Cash	�	480	219
Total Debt	0	8	4
Net Debt / (Cash)	�	-472	-215
Cash Flows & CapEx
Net Cash from Operations	-	262	-49
Total CapEx	0	-3	-0
Free Cash from Operations	-	259	-49
Returns to Shareholders
Dividends	0	-0	-0
Share Repurchases	-0	-0	-0

$ Mil \| FY: 12/31
Period End
Filing Date
Key Financials Quarterly
Total Revenue
Ebitda
Operating Income
Net Income
EPS
Key Financials TTM
Total Revenue TTM
Ebitda TTM
Operating Income TTM
Net Income TTM
Growth Rates Quarterly
Total Revenue Growth
EBITDA Growth
Operating Income Growth
Net Income Growth
Margins Quarterly
EBITDA Margin
Operating Income Margin
Net Income Margin
Cash & Debt
Total Cash
Total Debt
Net Debt / (Cash)
Cash Flows Quarterly
FCF from Operations
Cash Flows TTM
FCF from Operations TTM
Returns to Shareholders Quarterly
Dividends
Share Repurchases
Return on Invested Capital (ROIC) Quarterly
ROIC
Return on Invested Capital (ROIC) TTM
ROIC TTM

Segment Financials

null

Price Behavior

null

ADRX Betas & Captures as of 8/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta
Up Beta	�	�	�	�	�	�
Down Beta	�	�	�	�	�	�
Up Capture	0%	0%	0%	0%	0%	0%
Bmk +ve Days	10	21	32	68	138	427
Stock +ve Days
Down Capture	-0%	-0%	-0%	-0%	-0%	-0%
Bmk -ve Days	11	21	32	59	113	324
Stock -ve Days

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADRX
ADRX	-	-	-	-
Sector ETF (XLV)	26.9%	16.2%	1.28	-
Equity (SPY)	17.7%	13.0%	0.98	-
Gold (GLD)	14.7%	29.3%	0.46	-
Commodities (DBC)	46.8%	20.7%	1.75	-
Real Estate (VNQ)	4.5%	13.6%	0.07	-
Bitcoin (BTCUSD)	-25.5%	44.8%	-0.53	-

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADRX
ADRX	-	-	-	-
Sector ETF (XLV)	6.8%	15.2%	0.26	-
Equity (SPY)	13.3%	17.2%	0.59	-
Gold (GLD)	19.2%	18.8%	0.83	-
Commodities (DBC)	11.2%	19.5%	0.45	-
Real Estate (VNQ)	0.9%	18.9%	-0.06	-
Bitcoin (BTCUSD)	12.3%	52.6%	0.41	-

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ADRX
ADRX	-	-	-	-
Sector ETF (XLV)	10.9%	16.7%	0.53	-
Equity (SPY)	15.5%	17.9%	0.73	-
Gold (GLD)	12.1%	16.4%	0.61	-
Commodities (DBC)	8.7%	18.1%	0.39	-
Real Estate (VNQ)	4.8%	20.7%	0.19	-
Bitcoin (BTCUSD)	63.9%	66.2%	1.04	-

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Returns Analyses

null

SEC Filings

Expand for More

Report Date	Filing Date	Filing
06/30/2026	09/04/2026	S-1

Recent Forward Guidance

Updated 9/25/2026

Latest: null Earnings Reported N/A/N/A/N/A

null

Insider Activity

Updated null

Expand for Morenull

Investor Activity (13F)

Updated

13F holdings as of

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Core Cache Last Updated: 9/25/2026

Adarx Pharmaceuticals (ADRX)

Market Price (9/26/2026): $18.56 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

Adarx Pharmaceuticals (ADRX)

Market Price (9/26/2026): $18.56Market Cap: $-Sector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Adarx Pharmaceuticals (ADRX)

Interactive Breakdown

Better Bets vs. Adarx Pharmaceuticals (ADRX)

Peer Outperformance in Biotechnology

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Clinical Pipeline

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

Investor Activity (13F)

ADRX Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Market Price (9/26/2026): $18.56
Market Cap: $-
Sector: Health Care
Industry: Biotechnology